國立高雄大學圖資館 |

語系: 繁體中文

說明(常見問題)

圖資館首頁

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Locoregional radionuclide cancer the...

SpringerLink (Online service)

Locoregional radionuclide cancer therapyclinical and scientific aspects /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Locoregional radionuclide cancer therapyedited by Franklin C. L. Wong.
其他題名:	clinical and scientific aspects /
其他作者:	Wong, Franklin C. L.
出版者:	Cham :Springer International Publishing :2021.
面頁冊數:	xii, 268 p. :ill. (some col.), digital ;24 cm.
Contained By:	Springer Nature eBook
標題:	Radiopharmaceuticals.
電子資源:	https://doi.org/10.1007/978-3-030-56267-0
ISBN:	9783030562670$q(electronic bk.)

Locoregional radionuclide cancer therapyclinical and scientific aspects /
Locoregional radionuclide cancer therapyclinical and scientific aspects /[electronic resource] :edited by Franklin C. L. Wong. - Cham :Springer International Publishing :2021. - xii, 268 p. :ill. (some col.), digital ;24 cm.

Human Cancer- Epidemiology, Hallmarks, and Defense Strategies -- Cancer Treatment Modalities Systemic and Loco regional Approaches: Challenges and Opportunities of multidisciplinary approaches -- Cancer Radiotherapy: General Considerations and Human Radiobiology -- Radionuclide Cancer Therapy- Unsealed Alpha, Beta and Gamma Emitters -- Locoregional Therapy - Cancer Interventions with and without Radionuclides -- Radiation Dosimetry Considerations of Locoregional Radionuclide Cancer Therapy -- Voxel-based Targeted Radionuclide Therapy Dosimetry -- Locoregional Unsealed Radionuclide Cancer Therapy - Experimental Findings -- Animal Cancer Therapy Models - Ready Translation to Humans -- An Overview of Regulations of Radiopharmaceuticals -- Locoregional Radionuclide Cancer Therapy (LRCT) Using Sealed & Unsealed Radionuclides.

This book reviews locoregional radionuclide cancer therapies (LRCT) Proving an increasingly viable alternative to radiotherapy, radionuclide therapy includes a diversity of choices of well characterized biochemical and physiologic target molecules. The delivery and retention of radionuclides may be monitored by advanced imaging for exact tissue localization and for real-time dosimetry to enable personalized precision medicine. Radiopharmaceuticals in human cancer therapies are typically delivered in systemic routes but can also be designed for locoregional routes to harness pharmacokinetic advantages of higher payload and lower systemic toxicities. This book explores the latest advancements and clinical considerations of the locoregional approach. Throughout the chapters, the clinical and scientific bases of cancer treatment and the locoregional use of radionculides are explored. Mathematical models of radiation dosimetry of locoregional radionculdies on tissues are studied using common models for multiple commercially available radionuclides. Rodent and canine tumor models of LRCT are compared for selected radionuclides and radiopharmaceuticals. The practical aspects of radiopharmaceuticals production, marketing, transport, as well as radiation protection are reviewed. Finally, the combination of LRCT with immunotherapy and other cancer therapies and prospective future use of LRCT are discussed. This is a guide for practicing nuclear physicians, interventional radiologists, radiation oncologists, radiation scientists, veterinarians and oncologists to expand their knowledge base and to prepare for designing locoregional radionuclide cancer therapies in animals and in humans.

ISBN: 9783030562670$q(electronic bk.)

Standard No.: 10.1007/978-3-030-56267-0doiSubjects--Topical Terms:

347769
Radiopharmaceuticals.

LC Class. No.: RC271.R3

Dewey Class. No.: 616.9940642

Locoregional radionuclide cancer therapyclinical and scientific aspects /
LDR:03540nmm a2200325 a 4500 001 596544
003 DE-He213
005 20201208081959.0
006 m d
007 cr nn 008maaau
008 211013s2021 gw s 0 eng d
020 $a 9783030562670$q(electronic bk.)
020 $a 9783030562663$q(paper)
024 7 $a 10.1007/978-3-030-56267-0 $2 doi
035 $a 978-3-030-56267-0
040 $a GP $c GP
041 0 $a eng
050 4 $a RC271.R3
072 7 $a MMN $2 bicssc
072 7 $a MED080000 $2 bisacsh
072 7 $a MKR $2 thema
082 0 4 $a 616.9940642 $2 23
090 $a RC271.R3 $b L819 2021
245 0 0 $a Locoregional radionuclide cancer therapy $h [electronic resource] : $b clinical and scientific aspects / $c edited by Franklin C. L. Wong.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2021.
300 $a xii, 268 p. : $b ill. (some col.), digital ; $c 24 cm.
505 0 $a Human Cancer- Epidemiology, Hallmarks, and Defense Strategies -- Cancer Treatment Modalities Systemic and Loco regional Approaches: Challenges and Opportunities of multidisciplinary approaches -- Cancer Radiotherapy: General Considerations and Human Radiobiology -- Radionuclide Cancer Therapy- Unsealed Alpha, Beta and Gamma Emitters -- Locoregional Therapy - Cancer Interventions with and without Radionuclides -- Radiation Dosimetry Considerations of Locoregional Radionuclide Cancer Therapy -- Voxel-based Targeted Radionuclide Therapy Dosimetry -- Locoregional Unsealed Radionuclide Cancer Therapy - Experimental Findings -- Animal Cancer Therapy Models - Ready Translation to Humans -- An Overview of Regulations of Radiopharmaceuticals -- Locoregional Radionuclide Cancer Therapy (LRCT) Using Sealed & Unsealed Radionuclides.
520 $a This book reviews locoregional radionuclide cancer therapies (LRCT) Proving an increasingly viable alternative to radiotherapy, radionuclide therapy includes a diversity of choices of well characterized biochemical and physiologic target molecules. The delivery and retention of radionuclides may be monitored by advanced imaging for exact tissue localization and for real-time dosimetry to enable personalized precision medicine. Radiopharmaceuticals in human cancer therapies are typically delivered in systemic routes but can also be designed for locoregional routes to harness pharmacokinetic advantages of higher payload and lower systemic toxicities. This book explores the latest advancements and clinical considerations of the locoregional approach. Throughout the chapters, the clinical and scientific bases of cancer treatment and the locoregional use of radionculides are explored. Mathematical models of radiation dosimetry of locoregional radionculdies on tissues are studied using common models for multiple commercially available radionuclides. Rodent and canine tumor models of LRCT are compared for selected radionuclides and radiopharmaceuticals. The practical aspects of radiopharmaceuticals production, marketing, transport, as well as radiation protection are reviewed. Finally, the combination of LRCT with immunotherapy and other cancer therapies and prospective future use of LRCT are discussed. This is a guide for practicing nuclear physicians, interventional radiologists, radiation oncologists, radiation scientists, veterinarians and oncologists to expand their knowledge base and to prepare for designing locoregional radionuclide cancer therapies in animals and in humans.
650 0 $a Radiopharmaceuticals. $3 347769
650 0 $a Cancer $x Radiotherapy. $3 274201
650 1 4 $a Nuclear Medicine. $3 275838
650 2 4 $a Imaging / Radiology. $3 274007
650 2 4 $a Internal Medicine. $3 273839
700 1 $a Wong, Franklin C. L. $3 889386
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer Nature eBook
856 4 0 $u https://doi.org/10.1007/978-3-030-56267-0
950 $a Medicine (SpringerNature-11650)